Endometrial Cancer – Epidemiology Forecast to 2030

Endometrial cancer is the most common form of uterine cancer, arising from the endometrial lining of the uterus. Endometroid endometrial cancer is highly associated with increased estrogen levels, making it more common among young women, women with higher levels of body fat, and in those taking a form of exogenous estrogen.

In the 8MM, the diagnosed incident cases of endometrial cancer are expected to increase from 120,883 cases in 2020 to 133,690 cases in 2030, at an Annual Growth Rate (AGR) of 1.06%. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the diagnosed incident cases of endometrial cancer are expected to increase from 42,775 cases in 2020 to 47,947 cases in 2030, at an AGR of 1.21%. When examining the AGR by individual market, GlobalData forecasts that all markets will see an increase in the diagnosed incident cases of endometrial cancer during the forecast period. In 2020, there were 483,737 five-year diagnosed prevalent cases of endometrial cancer in the 8MM, which is expected to increase to 547,783 cases by 2030, at an AGR of 1.32%.

Scope

The Endometrial Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of endometrial cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).

It also includes a 10-year epidemiology forecast of the diagnosed incident and five-year diagnosed prevalent cases of endometrial cancer in these markets from 2020–2030. The incident cases are further segmented by age, International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis (I, II, IIIA, and IV), subtype (endometrioid, clear cell, serous, carcinosarcoma, and other), and associated biomarkers: microsatellite instability (MSI) high, mismatch repair deficiency (MMR-D), polymerase ε (POLE ) ultra mutation, MSI hypermutated, copy number low (CN low), copy number high (CN high), programmed death-ligand 1 (PDL-1), and human epidermal growth factor receptor 2 (HER-2) positivity.

The endometrial cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Endometrial Cancer Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global endometrial cancer market.

Quantify patient populations in the global endometrial cancer market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for endometrial cancer therapeutics in each of the markets covered.

Understand magnitude of endometrial cancer population by stage at diagnosis, subtypes, and mutations.

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Endometrial Cancer: Executive Summary

1.1 Related Reports

1.2 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of Endometrial Cancer

2.4.4 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage at Diagnosis

2.4.5 Diagnosed Incident Cases of Endometrial Cancer by Subtype

2.4.6 Diagnosed Incident Cases of Endometrial Cancer by Associated Biomarker

2.4.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer

2.5 Epidemiological Forecast for for Endometrial Cancer (2020–2030)

2.5.1 Diagnosed Incident Cases of Endometrial Cancer

2.5.2 Age-Specific Diagnosed Incident Cases of Endometrial Cancer

2.5.3 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage

2.5.4 Diagnosed Incident Cases of Endometrial Cancer by Subtype

2.5.5 Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarkers

2.5.6 Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage

2.5.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Risk Factors for Endometrial Cancer

Table 2: 8MM, Diagnosed Incident Cases of Endometrial Cancer by Subtype, Women, Ages ≥18 Years, N, 2020

List of Figures

Figure 1. 8MM, Diagnosed Incident Cases of Endometrial Cancer, Women, Ages ≥18 Years, 2020 and 2030

Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of Endometrial Cancer, Women, Ages ≥18 Years, N, 2020 and 2030

Figure 3: 8MM, Diagnosed Incidence of Endometrial Cancer (Cases per 100,000 population), Women, Ages ≥18 Years, 2020 and 2030

Figure 4: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer

Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage

Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer by Subtype

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarker

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage

Figure 9: 8MM, presents the sources used to forecast the five-year diagnosed prevalent cases of endometrial cancer in the 8MM.

Figure 10: Diagnosed Incident Cases of Endometrial Cancer, 8MM, Women, Ages ≥18 years, 2020

Figure 11: 8MM, Diagnosed Incident Cases of Endometrial Cancer by Age, Women, N, 2020

Figure 12: 8MM, Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage, Women, Ages ≥18 Years, N, 2020

Figure 13: 8MM, Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarker, Women, Ages ≥18 Years, N, 2020

Figure 14: 8MM, Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage, Women, Ages ≥18 Years, N, 2020

Figure 15: 8MM, Five-Year Diagnosed Prevalent Cases of Endometrial Cancer, Women, Ages ≥18 Years, N, 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports